| scholarly article | Q13442814 |
| P50 | author | Narikazu Boku | Q88572199 |
| P2093 | author name string | Ken Kato | |
| Do-Youn Oh | |||
| Taroh Satoh | |||
| Masahiro Tsuda | |||
| Jae Yong Cho | |||
| Keiko Minashi | |||
| Hyun Cheol Chung | |||
| Li-Tzong Chen | |||
| Sang Cheul Oh | |||
| Takao Tamura | |||
| Won Ki Kang | |||
| Yoon-Koo Kang | |||
| Jen-Shi Chen | |||
| Keisho Chin | |||
| Jong Gwang Kim | |||
| Li-Yuan Bai | |||
| Keun-Wook Lee | |||
| Yasuo Hamamoto | |||
| Kei Muro | |||
| Takaki Yoshikawa | |||
| Kun-Huei Yeh | |||
| Yee Chao | |||
| Min-Hee Ryu | |||
| Hiroki Sameshima | |||
| P2860 | cites work | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 |
| Nivolumab in previously untreated melanoma without BRAF mutation | Q29620688 | ||
| Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 | ||
| Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 | ||
| Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer | Q33738921 | ||
| Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study | Q33823259 | ||
| Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial | Q38906747 | ||
| Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial | Q39668099 | ||
| Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction | Q39991776 | ||
| Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck | Q43164702 | ||
| Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma | Q47551890 | ||
| Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Q47745009 | ||
| A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. | Q49917250 | ||
| Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial | Q53837214 | ||
| Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer. | Q54620120 | ||
| Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial | Q57812653 | ||
| Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | Q60142201 | ||
| Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach | Q64076485 | ||
| Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 | Q90568939 | ||
| Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study | Q92806484 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 510-519 | |
| P577 | publication date | 2019-12-20 | |
| P1433 | published in | Gastric Cancer | Q15724608 |
| P1476 | title | A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data | |
| P478 | volume | 23 |
| Q96950785 | Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer |
| Q96155607 | Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers |
| Q100728126 | Seven-Gene Signature Based on Glycolysis Is Closely Related to the Prognosis and Tumor Immune Infiltration of Patients With Gastric Cancer |
Search more.